Introduction
The set of morphologic alterations observed in the end stages of chronic liver diseases (CLDs), characterized by a deranged angio-architecture of the liver parenchyma, are described as 'cirrhosis'. The wound-healing reaction subsequent to a chronic injury leads to the formation of regenerative parenchymal nodules encapsulated and separated by fibrotic septa altering the normal lobular archi-tecture [1] . Essential alterations of the vascular system in cirrhosis are: formation of intrahepatic shunts, derangement of the vascular network in portal tracts, capillarization of sinusoids, perisinusoidal fibrosis, vascular thrombosis, under-perfusion of lobular parenchyma and resulting tissue hypoxia [2] . Overall, cirrhosis could be regarded as a vascular disease of the liver. Consequence of all these changes is the development of portal hypertension (PH) and its life-threatening complications. Furthermore, the constant attempt of regeneration occurring in a fibro-inflammatory tissue microenvironment is responsible for the potential occurrence of hepatocellular carcinoma (HCC).
There is increasing awareness that the concept of liver cirrhosis as a static and irreversible end-stage condition has now become inappropriate. Indeed, the advances in understanding the mechanisms of chronic fibrogenetic liver diseases have led to the conclusion that the histological semi-quantitative scores, classically used in the the attempt to define disease grade (necro-inflammatory activity) and stage (tissue fibrosis) on biopsy specimens, as well as the traditional classification of compensated and decompensated disease based on the degree of portal pressure and the occurrence of clinical complications, do not recapitulate and represent the complexity and the spectrum of different stages of advanced-stage CLD and their dynamic development [3] .
Furthermore, it is now clear that the different types of CLD have characteristic patterns of fibrotic evolution, with distinctive predominant mechanisms and fibrogenetic cell types [4] .
In the era in which agents leading to a permanent suppression of hepatitis B virus (HBV) and new antivirals able to eradicate hepatitis C virus (HCV) in an extremely high percentage of cases have become real therapeutic options, regression of liver fibrosis and even of cirrhosis has become a concrete possibility.
Mechanisms of Hepatic Fibrogenesis and the Development of Cirrhosis

Chronic Wound Healing and Fibrogenesis
The chronic wound healing process triggered by reiterated liver tissue damage due to infective, metabolic, autoimmune, cholestatic or toxic causes activates a series of pro-fibrogenetic mechanisms which lead to a variable degree of necrosis/apoptosis of hepatic cells associated with an inflammatory infiltration and the progressive accumulation of fibrillar extracellular matrix (ECM) [5, 6] .
The continuous accumulation of fibrillar ECM is associated with its simultaneous degradation and remodeling, making fibrogenesis a potentially reversible dynamic process. However, with the advancement of CLD, fibrosis becomes progressive and to a certain extent irreversible, due to the exhaustion of the degradative machinery [5] .
The wound healing process is characterized by a cascade of biological events, which involve cells and soluble factors, aimed at resolving tissue injury ( fig. 1 ). These events and effectors are disposed in a natural sequence with activation of the next step preceded by the resolution of the previous phase [7] . In the presence of a single tissue insult, this mechanism is highly effective, but in the context of a chronic liver injury, deposition of fibrillar matrix rather than organized tissue regeneration becomes the best natural option in order to maintain tissue continuity, leading to progressive scarring of the tissue.
The modification in ECM composition occurring in this process, with a predominance of collagen types I and III, has obvious physiological, biochemical and biomechanical implications. The accumulation of fibrillar ECM in the sinusoidal structures (capillarization of sinusoids) alters the normal exchange of macromolecules and oxygen between hepatocytes and sinusoidal blood, induces profound changes in the expression of integrins and other cell adhesion molecules, acts as reservoir for pro-inflammatory and pro-fibrogenetic mediators and progressively increases tissue stiffness, a key pro-fibrogenetic mechanism leading to the modulation of several cellular functions (growth, migration, gene expression) [5] [6] [7] .
Hepatic stellate cell (HSC) represents the main fibrogenetic cell type in the liver. Presenting ultrastructural features of vascular pericytes, they also have a potential role in the regulation of sinusoidal blood flow. The processes of HSC activation and phenotypical transformation into myofibroblasts, as well as their pro-fibrogenetic role, have been extensively clarified. It is now clear that distinct ECM-producing cells, each with a distinct localization and a characteristic immunohistochemical and/or electron microscopic phenotype, are likely to contribute to liver fibrosis [5, 6] . These include the following: fibroblasts and myofibroblasts of the portal tract, smooth muscle cells localized in vessel walls and myofibroblasts localized around the centrilobular vein. Myofibroblasts may also derive from a population of circulating fibroblast-like cells derived from bone marrow stem cells, called 'fibrocytes' [8] . The relative participation of these different ECM-producing cells depends on the pattern of fibrosis evolution.
Although cell biology of liver fibrosis has been mostly framed around activated HSCs and, in general, myofibro- blast-like cells, other cells play a fundamental role in the fibrogenetic process. In particular, macrophages are indispensable for both fibrosis progression and regression [9] and their activity is modulated by the direction of the cytokines and other soluble factors network toward progression or resolution. Platelet aggregation/degranulation, the activation of the complement system and the coagulation cascade, represent initial events of the wound healing reaction. Accordingly, anticoagulants or antiplatelet agents have been shown to prevent fibrosis by acting on HSCs in several animal models [10] . Cholangiocytes play a major role and contribute to the peribiliary fibrogenetic processes in CLD characterized by damage, proliferation and activation of the biliary epithelium. These cells express a wide range of pro-fibrogenetic molecules and, when activated, stimulate fibrogenetic, apoptotic and proliferative response through an intense crosstalk with portal fibroblasts/myofibroblasts and HSC mediated by pro-inflammatory and chemotactic cytokines such as IL-6, TNF-α, IL-8 and MCP-1 [11] .
There is increasing evidence that the alterations of the mechanisms of innate immunity occurring in systemic pro-inflammatory and pro-fibrogenetic status and bacterial translocation affect CLD progression [12] [13] [14] [15] . In particular, a combination of dysbiosis and increased intestinal permeability, altered gut defenses and reduced immunological reactivity leads to increased migration of bacteria or bacterial products from the intestinal lumen to mesenteric lymph nodes or other extraintestinal sites [12] . Recently, the attention is focused on bacterial products named pathogen-associated molecular patterns (PAMPs): lipoproteins, bacterial DNA and doublestranded RNA, recognized by pattern recognition receptors (PRRs) present on a wide variety of cells [13] . The interaction between PAMPs and PRRs serves as a firstline defence during infection and activates numerous pro-inflammatory cytokine and chemokine responses. Fibroblasts, myofibroblasts and vascular pericytes express a variety of PRRs (including toll-like receptors) which, when bound by their ligands, can promote the activation/differentiation of these cells into collagen-producing myofibroblasts and the establishment of a proinflammatory/pro-fibrogenetic condition in the portal circulation [14, 15] .
Neo-Angiogenesis
In the last few decades, increasing attention has been given to the key interplay between neo-angiogenesis and fibrogenesis and its role in the progression of CLD toward cirrhosis.
Angiogenesis and upregulation of vascular endothelial growth factor (VEGF) have been documented in experimental models of acute and chronic liver injury [16] as well as in specimens from human fibrotic/cirrhotic liver and HCC [17, 18] .
When activated by hypoxia occurring in the context of a chronic wound healing reaction, HCS represent a significant source of angiogenic cytokines and tend to acquire a generic 'pro-angiogenic' phenotype. They represent the target of the multiple actions of VEGF and angiopoietin 1, including stimulation of proliferation, collagen type I synthesis and recruitment of other HSC [19] .
The intrahepatic vascular remodeling occurring in CLD (capillarization of sinusoids, development of intrahepatic shunts) leads to increased hepatic resistance, PH and decreased effective hepatocyte perfusion. The process of revascularization is characterized by a chaotic pattern; many of the neo-formed vessels have a 'blind end' and only a minority of attempts results in portal-central anastomoses. These vascular structures follow irregular patterns and are surrounded by fibrotic tissue containing contractile cells (activated HSC, myofibroblasts). This leads to increased hepatic resistance and further reduction of the effective perfusion of the hepatocytes, thus reiterating the hypoxic stimulus to angiogenesis and fibrogenesis [20] .
Fibrosis and Portal Hypertension
PH is primarily the result of an increased intrahepatic resistance caused by architectural distortion (fibrous tissue, regenerative nodules), endothelial dysfunction leading to intrahepatic vasoconstriction and the formation of intrahepatic vascular shunts between afferent and efferent vessels of the liver [21, 22] . Subsequently, PH is aggravated by an increase of portal and hepatic arterial blood flow.
Hepatic venous pressure gradient (HVPG), an indirect measure of portal pressure, is the best predictor of development of PH [23, 24] . Progressive increases in HVPG correlate with increasing severity of liver disease: normal, chronic hepatitis, pre-cirrhosis and cirrhosis [25] . Despite the fact that histological features of disease progression within the stage of cirrhosis (since this is identified by the highest value of the currently used scoring systems) have not been traditionally linked to clinical outcomes, the analysis of some histologic features in cirrhotic liver biopsies may have important prognostic implications. For example, the thickness of fibrous septa correlates with HVPG and is an independent predictor of both clinically significant PH [26] and clinical decompensation [27] .
The recently introduced feasibility to measure the quantity and the distribution of collagen as collagen proportional area (CPA), a new histological marker obtained by digital video imaging analysis, has allowed to better define the relationship between evolution of fibrosis and worsening of PH. Furthermore, scoring cirrhosis with a continuous scale may allow the prediction of relevant clinical outcomes [28, 29] .
Etiology-Driven Fibrogenetic Mechanisms and Patterns
In recent years, the increasing awareness that different CLDs have distinct patterns of fibrotic development has led to the concept of 'etiology-driven cirrhosis' [30, 31] .
The different patterns of fibrogenetic evolution are related to various factors, such as the topographic localization of tissue damage, the dynamics of the necro-inflammatory infiltrate, the distribution of fibrosis, the relative concentration of pro-fibrogenetic factors, the main profibrogenetic mechanism(s) as well as the prevalent cellular effectors. Time to disease progression, distribution of fibrosis and onset/progression of PH are correlated and depend on the etiological agent.
The fibrotic pattern of chronic viral hepatitis is characterized by portal-central septa (likely the results of portal-central bridging necrosis), the presence of 'interface' hepatitis and the development of portal-portal septa and blind-end intraparenchymal septa and a rapid derange- 378 ment of the vascular connections with the portal system, which causes early PH. In biliary diseases, instead, the central vein and its connections with the portal tract are preserved until late stages and fibrosis. This is due to the co-proliferation of reactive bile ductules and periductal myofibroblast-like cells at the portal-parenchymal interface, which tends to follow a portal-to-portal direction, leading to the formation of portal-portal septa surrounding liver nodules and to the development of pre-sinusoidal resistance to portal flow. In alcoholic and metabolic liver diseases, the deposition of fibrillar matrix is concentrated around the sinusoids (capillarization) and around groups of hepatocytes (chicken-wire pattern). Finally, fibrosis secondary to venous outflow problems (e.g. chronic heart failure) is characterized by development of central-to-central septa and 'reversed lobulation' ( table 1 ).
Recent studies quantifying the amount of fibrosis present on explanted cirrhotic livers of different etiologies by means of CPA provide a proof of concept of the above considerations [28, 32] .
Reversibility of Fibrosis and Cirrhosis
Evidence of fibrosis and even cirrhosis regression has been reported in CLDs of various etiologies, including viral hepatitis [33, 34] , autoimmune hepatitis [35] , alcoholic and non-alcoholic steatohepatitis [36, 37] , although, in most cases, the experienced liver pathologists who analyzed these results have been in agreement only for a variable degree of fibrosis regression and not for cirrhosis reversion [38, 39] . Furthermore, it has to be underlined that the background scientific information is based on data obtained in experimental animal models in which liver cirrhosis can be induced in only a few weeks and quickly reverted after the suspension of the exposure to the causative agent. This possibility is far from being substantiated in humans. Available evidence suggest that even extensive fibrosis regression is characterized by the persistence of veno-portal adhesions and 'arterialized' sinusoids in the context of intrahepatic arteriovenous shunts [40] , raising serious doubts about a potential regression of the intrahepatic vasculature abnormalities in human cirrhotic liver.
Critical events for the reversibility of fibrosis are the more or less rapid switch-off of the chronic wound healing process characterized by the progressive reduction of necro-inflammation and the following reduction of the number of activated HSC through pathways of apoptosis, senescence and reversion to quiescence. In addition, it has been demonstrated that macrophages play a key role in the resolution of fibrosis, and data have raised the possibility that different classes of macrophages respectively responsible for fibrosis progression or regression might exist [41] . Cirrhosis has a very broad spectrum of variants (early, fully developed, 'active' and 'inactive') and there is clear lack of an accurate scoring system able to identify the different evolution phases of the advanced-stage CLD and to better describe the dynamic development of the disease, its pathophysiology or the impact of tissue fibrosis, neo-angiogenesis, necro-inflammation and attempted regeneration on the often life-threatening clinical manifestations. At the base of the problem is the fact that the staging of fibrosis is obtained using semi-quantitative scoring systems, in which cirrhosis is always represented by the highest score and considered as an end stage of CLD [42] . On the other hand, the term 'cirrhosis' identifies an advanced phase of CLD that per se is neither morphologically or clinically an end stage, particularly with the prospective of novel treatments able to stabilize or even reduce tissue fibrosis. The currently used classification of cirrhotic patients into 5 stages on the basis of the major clinical manifestations of their disease (stage 1: compensated with no esophageal varices; stage 2: compensated with esophageal varices, stage 3: ascites, stage 4: gastrointestinal bleeding, stage 5: infections and renal failure) is also inadequate in predicting the evolution of disease and life-threatening events [2, 3] .
It is expected that the ability to revert and the relevance of different mechanisms involved in the regression of fibrosis may differ according to the effective stage of the disease (pre-cirrhosis, early cirrhosis, advanced/established cirrhosis). In fact, several studies have demonstrated the capacity of the healing liver to reabsorb scar tissue following an effective causative treatment (i.e. sustained viral response (SVR), abstinence from alcohol etc.), while the possibility of established cirrhosis to reverse to normal is still quite doubtful [41] . Along these lines, it is clear that scar tissue in the liver of patients with a long-standing CLD is characterized by different stages of biochemical and biological evolution compared to that of a disease with recent onset. Within the same liver, in fact, there are different types of scar tissue with different potential and dynamics of reversibility once the etiological agent is eradicated and/or an anti-fibrogenetic therapy is applied.
Fibrotic deposition related to recent disease that is characterized by the presence of thin reticulin fibers, often in the presence of a diffuse inflammatory infiltrate, is likely fully reversible, whereas long standing fibrosis, characterized by extensive collagen cross-linking by tissue transglutaminase, presence of elastin, dense acellular/ paucicellular ECM and decreased expression and/or activity of specific metalloproteinases, is not [43] . Even more, it has been shown that long-term fibrogenesis occurring in human CLD is characterized by a progressive resistance to apoptosis of HSCs/myofibroblasts with the consequent immovability of a critical mass of pro-fibrogenetic cells [44] .
PH reflects the histological changes typical of advanced stage liver disease (acellular fibrosis, extensive collagen crosslinking, elastin deposition) as well as the disease severity. When HVPG overcomes 12 mm Hg, cirrhosis becomes a systemic disease, where severity and evolution are largely independent of liver tissue fibrosis. Therefore, the absence of a significant PH seems to be a crucial determinant for the possibility of fibrosis regression in advanced-stage CLD [41] .
The new interferon-free regimens for the treatment of HCV allow a SVR in almost 100% of the treated patients including patients with cirrhosis. Hence, viral eradication can also be achieved in advanced stages of the disease. SVR is likely to be followed by a decline of necroinflammation and fibrosis progression, as well as by an improvement of PH and its clinical manifestations, risk of HCC, liver-related mortality and liver transplantation [45, 46] .
Similarly, nucleoside/nucleotide analogues (NUC) agents suppressing HBV DNA levels prevent disease progression and improve patients' survival. Long-term treatment of HBV with NUC can result in histological reduction or stabilization of liver fibrosis in most patients [47, 48] .
However, obtaining a SVR in patients with HCV-related cirrhosis does not necessarily prevent the immediate risk of decompensation and/or of HCC. In fact, it has been reported that SVR significantly reduces the risk of decompensation and liver-related death only in those patients categorized as 'stage 1', who do not present clinically significant PH. Furthermore, HCV clearance in compensated patients with a significant grade of PH does not lead to the abolition of the risk of progression toward decompensation or to a significant reduction of PH [46] . In this context, it is important to keep in mind that despite the evidence of fibrosis (and even cirrhosis) regression in patients undergoing SVR, other processes such as ductular proliferation, loss of lobular zonation, portal inflammation and sinusoidal capillarization may not regress following SVR [49] .
It is likely that, beyond a certain level, the fibrogenetic process may acquire a relative autonomy, leading to a further progression of the disease independently from the discontinuation of the causative agent and the consequent reduction of hepatocellular necrosis and inflammation. This may depend on the significant hyperplasia of activated HSCs and myofibroblasts and the activation of anti-apoptotic pathways in these cells [50] , as well as the derangement of the hepatic angio-architecture consequent to neo-angiogenesis and the elevated tissue tension due to fibrotic tissue contraction, which are only minimally affected by the reduction of necro-inflammation. In addition, the persistence of pro-fibrogenetic cofactors such as excessive alcohol intake and baseline metabolic factors is likely to negatively influence the extent and rapidity of fibrosis regression despite an effective etiological treatment.
Since there is clear sufficient evidence that some individual factors influence the rate of fibrosis progression leading to the differentiation of patients in slow, intermediate and fast 'fibrosers', it is conceivable that the presence of genetic/epigenetic determinants affecting the rapidity of fibrosis progression may also influence fibrosis regression [41] .
Conclusions
Thanks to the advancement in understanding the mechanisms leading to advanced-stage CLD, it appears more and more clear that the disease is sustained by different prevalent mechanisms depending on the triggering etiology and that the word 'cirrhosis', traditionally implying a static and irreversible condition, is not reflecting the actual dynamicity of the underlining processes.
Accordingly, there is a current need to redefine cirrhosis in order to better reflect its progression, reversibility and prognosis, as well as its relationship with PH and fibrogenesis.
This potentially calls for different morphological classifications, different non-invasive diagnostic and prognostic indicators, different etiology-driven and/or antifibrotic therapies and, most importantly, different expectations on the effective reversibility of fibrosis and cirrhosis.
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